Part of the four-member HER family of proteins, HER3 is known to work with HER2 to play a role in treatment resistance.

HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining ...

Among patients with human epidermal growth factor receptor 2 (HER2, IHC 3+ or IHC 2+/ISH+) positive unresectable and/or metastatic gastric or gastroesophageal cancer, Enhertu (trastuzumab deruxtecan) ...

Focus shifts to EO-1022, a HER3 ADC with glycan site-specific conjugation ... with moderate to strong staining intensity (IHC 2+/3+) as determined by immunohistochemistry. Objective response rate: the ...